Reuters logo
BRIEF-Myriad Genetics says EndoPredict outperforms Oncotype DX in predicting long-term recurrence of breast cancer
December 9, 2016 / 12:33 PM / a year ago

BRIEF-Myriad Genetics says EndoPredict outperforms Oncotype DX in predicting long-term recurrence of breast cancer

Dec 9 (Reuters) - Myriad Genetics Inc :

* The EndoPredict test significantly outperforms the first-generation test in predicting the risk of node-negative and node-positive breast cancer recurrence

* Myriad Genetics - test shows EndoPredict was superior to Oncotype DX, a first-generation test, in predicting long-term recurrence of breast cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below